In a double-blind trial, we randomly assigned 14,264 patients with nonvalvular atrial fibrillation who were at increased risk for stroke to receive either rivaroxaban (at a daily dose of 20 mg) or ...

The Bottom Line A new study examined more than 5100 adults with nonvalvular AF who were starting oral anticoagulation therapy. Patients were divided into 4 groups, each with different baseline ...

Data from a Japanese registry may be useful for characterizing frailty among older patients with nonvalvular atrial fibrillation (NVAF), possibly opening the door to better treatment decisions and ...

Incidence of nonvalvular atrial fibrillation on ibrutinib compared to other tyrosine kinase inhibitors: A large multi-institution general practice study.

Background: Too few patients with nonvalvular atrial fibrillation (NVAF) receive appropriate antithrombotic therapy. We tested the short-term (primary outcome) and long-term (secondary outcome) effect ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

Multiple considerations come into play when choosing anticoagulant therapy for a patient with atrial fibrillation, a condition that greatly increases the risk for stroke.

Background: Nonvalvular atrial fibrillation (AF) is common in elderly patients, who face an elevated risk of stroke but difficulty sustaining warfarin treatment. Methods and Results-There were ...

Another Factor Xa inhibitor, apixaban, was investigated in the AVERROES trial, [11] and was compared with aspirin with respect to stroke prevention in 5599 patients with nonvalvular AF with >one ...

In A Subanalysis, The Benefits Of Eliquis® (apixaban) Vs. Warfarin In Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation Were Consistent, Regardless Of Blood Pressure ...